Literature DB >> 17136954

The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design.

A Sonia Buist1, William M Vollmer, Sean D Sullivan, Kevin B Weiss, Todd A Lee, Ana M B Menezes, Robert O Crapo, Robert L Jensen, Peter G J Burney.   

Abstract

Quantifying COPD prevalence worldwide is needed to document COPD's effect on disability, health care costs, and impaired quality of life and to inform governments and health planners. As an adjunct to data obtained from population-based studies, and for countries where a fully powered prevalence survey cannot be done, modeling of COPD prevalence and its economic burdens can help estimate potential health care needs and costs. For comparability, standardized methods for prevalence surveys are needed that can be used in countries at all levels of economic development. The Burden of Obstructive Lung Disease (BOLD) Initiative has developed a set of methods for estimating COPD prevalence and a model for assessing its economic impact, and piloted these methods in China and Turkey. The methods were revised to reflect the findings in the pilot studies, and BOLD is now making the standardized methods available worldwide. The BOLD Operations Center provides training, materials, quality control, and data analysis. BOLD emphasizes data quality control at every stage of the process. Data from paper forms completed in the field are entered electronically to a specially designed secure Web platform. Pre- and post-bronchodilator spirometry testing is done on all participants, and all spirometry data are reviewed for quality. Questionnaires are used to obtain information about respiratory symptoms, health status, exposure to risk factors, and economic data about the burden of COPD. BOLD's standardized methods will provide a uniform way to compare COPD burden within and between countries, and where differences are found, to explore explanations for these differences.

Entities:  

Mesh:

Year:  2005        PMID: 17136954

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  106 in total

1.  [COPD today and in the year 2020].

Authors:  Bernd Lamprecht; Michael Studnicka
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 2.  Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD.

Authors:  R N van Zyl Smit; M Pai; W W Yew; C C Leung; A Zumla; E D Bateman; K Dheda
Journal:  Eur Respir J       Date:  2010-01       Impact factor: 16.671

3.  Reproducibility and validity of a handheld spirometer.

Authors:  R Graham Barr; Kimberly J Stemple; Sonia Mesia-Vela; Robert C Basner; Susan J Derk; Paul K Henneberger; Donald K Milton; Brenda Taveras
Journal:  Respir Care       Date:  2008-04       Impact factor: 2.258

4.  Predictors of dyspnoea prevalence: results from the BOLD study.

Authors:  Rune Grønseth; William M Vollmer; Jon A Hardie; Inga Sif Ólafsdóttir; Bernd Lamprecht; A Sonia Buist; Louisa Gnatiuc; Amund Gulsvik; Ane Johannessen; Paul Enright
Journal:  Eur Respir J       Date:  2013-10-31       Impact factor: 16.671

5.  Understanding the true burden of COPD: the epidemiological challenges.

Authors:  Sundeep S Salvi; Roslina Manap; Richard Beasley
Journal:  Prim Care Respir J       Date:  2012-09

6.  Prevalence of chronic obstructive pulmonary disease among stable chronic disease subjects in primary care in Trinidad, West Indies.

Authors:  Peterson Thorington; Maria Rios; Gina Avila; Josia Henry; C Haynes; Lexley M Pinto Pereira; Terence Ar Seemungal
Journal:  J Thorac Dis       Date:  2011-09       Impact factor: 2.895

7.  Network vs. pairwise meta-analyses: a case study of the impact of an evidence-synthesis paradigm on value of information outcomes.

Authors:  Zafar Zafari; Kristian Thorlund; J Mark FitzGerald; Carlo A Marra; Mohsen Sadatsafavi
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

8.  Lies, damned lies and mortality statistics?

Authors:  A L Hansell
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

9.  Present and future costs of COPD in Iceland and Norway: results from the BOLD study.

Authors:  R Nielsen; A Johannessen; B Benediktsdottir; T Gislason; A S Buist; A Gulsvik; S D Sullivan; T A Lee
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

10.  Can a normal peak expiratory flow exclude severe chronic obstructive pulmonary disease?

Authors:  R Perez-Padilla; W M Vollmer; J C Vázquez-García; P L Enright; A M B Menezes; A S Buist
Journal:  Int J Tuberc Lung Dis       Date:  2009-03       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.